218 related articles for article (PubMed ID: 11249651)
1. Delivery systems for molecular vaccination.
Sheikh NA; al-Shamisi M; Morrow WJ
Curr Opin Mol Ther; 2000 Feb; 2(1):37-54. PubMed ID: 11249651
[TBL] [Abstract][Full Text] [Related]
2. Fully mobilizing host defense: building better vaccines.
Raychaudhuri S; Rock KL
Nat Biotechnol; 1998 Nov; 16(11):1025-31. PubMed ID: 9831030
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines--challenges in delivery.
Pachuk CJ; McCallus DE; Weiner DB; Satishchandran C
Curr Opin Mol Ther; 2000 Apr; 2(2):188-98. PubMed ID: 11249641
[TBL] [Abstract][Full Text] [Related]
4. An overview of adjuvant formulations and delivery systems.
García A; De Sanctis JB
APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
[TBL] [Abstract][Full Text] [Related]
5. Particulate delivery systems for vaccines: what can we expect?
Bramwell VW; Perrie Y
J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973
[TBL] [Abstract][Full Text] [Related]
6. Immunity in response to particulate antigen-delivery systems.
Storni T; Kündig TM; Senti G; Johansen P
Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.
Jiang W; Gupta RK; Deshpande MC; Schwendeman SP
Adv Drug Deliv Rev; 2005 Jan; 57(3):391-410. PubMed ID: 15560948
[TBL] [Abstract][Full Text] [Related]
8. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant formulations for experimental vaccines.
Stewart-Tull DE
Methods Mol Med; 2003; 87():175-94. PubMed ID: 12958456
[No Abstract] [Full Text] [Related]
10. Microparticles as vaccine adjuvants and delivery systems.
O'Hagan DT; Singh M
Expert Rev Vaccines; 2003 Apr; 2(2):269-83. PubMed ID: 12899577
[TBL] [Abstract][Full Text] [Related]
11. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
De Magistris MT
Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
[TBL] [Abstract][Full Text] [Related]
12. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
13. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
14. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines.
Waeckerle-Men Y; Groettrup M
Adv Drug Deliv Rev; 2005 Jan; 57(3):475-82. PubMed ID: 15560953
[TBL] [Abstract][Full Text] [Related]
15. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments.
Heegaard PM; Dedieu L; Johnson N; Le Potier MF; Mockey M; Mutinelli F; Vahlenkamp T; Vascellari M; Sørensen NS
Arch Virol; 2011 Feb; 156(2):183-202. PubMed ID: 21170730
[TBL] [Abstract][Full Text] [Related]
16. Human Flt-3-ligand-mobilized dendritic cells require additional activation to drive effective immune responses.
Diener KR; Moldenhauer LM; Lyons AB; Brown MP; Hayball JD
Exp Hematol; 2008 Jan; 36(1):51-60. PubMed ID: 17949888
[TBL] [Abstract][Full Text] [Related]
17. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
18. Virosomes for antigen and DNA delivery.
Daemen T; de Mare A; Bungener L; de Jonge J; Huckriede A; Wilschut J
Adv Drug Deliv Rev; 2005 Jan; 57(3):451-63. PubMed ID: 15560951
[TBL] [Abstract][Full Text] [Related]
19. Jump-starting the immune system: prime-boosting comes of age.
Woodland DL
Trends Immunol; 2004 Feb; 25(2):98-104. PubMed ID: 15102369
[TBL] [Abstract][Full Text] [Related]
20. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
